Summary of Loading Off Q2 > Annual Report Bottom - As At
Summary of Loading Off Q2 > Annual Report Bottom - As At Close March 13.
Bought at .0005:
January 19: 3M
January 23: 3M
Total: 6M
Bought at .0004:
August 23: 9.5M
September 1: 1.5M
September 6: 4M
September 7: 1M
September 11: 5M
September 15: 63M
September 21: 1M
September 26: 62M
September 27: 65M
September 28: 36M
September 29: 7M
October 2: 13M
October 3: 1M
October 5: 5M
October 6: 11M
October 9: 4M
October 11: 14M
October 12: 1M
October 16: 9M
October 17: 6M
October 18: 2M
October 19: 1M
October 23: 2M
October 24: 3M
October 25: 7M
October 26: 16M
October 31: 3M
November 2: 1M
November 3: 3M
November 6: 4M
November 7: 1M
November 9: 1M
November 10: 4M
November 14: 3M
November 16: 1M
November 17: 5M [discounting double print of a 2M buy]
November 20: 10M
November 21: 2M
November 22: 2M
November 24: 2M
November 27: 4M
November 28: 1M
November 30: 3M
December 5: 2M
December 12: 1M
December 14: 1M
December 28: 9M
December 29: 4M
January 3: 7M
January 5: 1M [rounded down from 1.4M]
January 8: 1M
January 11: 51M
January 19: 20M
January 24: 3M
January 29: 1M [rounded up from 684K with 500K from January 26]
January 30: 2M [rounded up from 1.7M]
February 2: 6M
February 5: 2M
February 6: 4M
February 8: 5M
February 9: 2M
February 12: 2M
February 13: 2M
February 14: 3M
February 15: 8M
February 16: 1M
March 2: 4M [rounded up]
March 5: 4M [rounded down]
March 6: 1M
March 7: 1M [rounded up]
March 8: 2M [rounded down]
March 9: 3M [rounded up]
March 12: 11M
March 13: 5M
Total: 566M
Bought at .0003:
September 15: 1M
October 2: 3M
October 6: 3M
October 9: 7M
October 17: 1M [rounded up from 850K]
November 22: 3M
November 30: 1M
December 1: 11M
December 5: 30M
December 6: 4M [rounded down from 4.4M]
December 7: 8M
December 8: 13M
December 12: 2M
December 14: 96M
December 15: 13M
December 18: 5M
December 19: 3M
December 21: 2M
December 22: 2M
December 27: 2M
December 28: 3M
December 29: 8M
January 2: 1M [rounded down from 1.5M]
January 3: 13M
January 4: 1M [rounded up from 800K]
January 10: 1M
January 18: 13M [rounded down from 13.4M]
February 6: 1M
February 12: 3M
February 14: 1M [rounded up]
February 16: 1M
February 21: 2M [rounded down]
March 1: 1M [rounded up]
Total 259M
American EcoFuels Inc (AEFI) Stock Research Links
"Per Ardua Ad Astra" - "Through Adversity To The Stars"
A very apposite motto for those who trade successfully in the OTC market..
All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....
Continue Reading
A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...
Continue Reading
Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...
Continue Reading
Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...
Continue Reading
Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...
Continue Reading
Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...
Continue Reading
Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...
Continue Reading
Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...
Continue Reading
Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...
Continue Reading
Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...
Continue Reading
"blog__more">
More News Articles